NEW YORK (GenomeWeb) – Accelerate Diagnostics' first quarter revenues dropped 13 percent year over year, the company said in a regulatory document on Friday.

In a Form 10-Q filed with the US Securities and Exchange Commission, the Tucson, Ariz.-based firm reported revenues of $14,000 for the three months ended March 31, compared to $16,000 in the year-ago quarter. Revenues for both quarters derived from licensing and royalty revenues.

The drop resulted from fluctuations in partner sales volumes, which affected Accelerate, it said in its SEC document.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.